HGS v Lilly: Day 2

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

HGS v Lilly: Day 2

HGS’s patent for Neutrokine-a contains a “lot of guff” according to Lord Justice Neuberger – but should that invalidate the patent?

That was the key question discussed during the second day of the UK Supreme Court's hearing in HGS v Lilly.



While the judge described the language relating to industrial application as “guff”, HGS’s barrister, Simon Thorley QC preferred to call it “scientific hopes for the future”.



HGS’s Neutrokine-α patent includes many projections of what the uses of the invention could be. Lilly, which challenges the patent's validity, argues that these are too numerous and too far-fetched and that it is unclear to the reader what the actual industrial applications are.



“They frankly threw everything in,” Andrew Waugh QC, who represents Lilly, told the Court today. “They wanted to keep their options open,” he added.



Waugh argued that equal measure and conviction had been given in the patent to all the unproven activities of Neutrokine-α as well as the activities expected from the general knowledge, so the reader could not easily identify its industrial application.



Neuberger asked whether the EPO Technical Board of Appeal (TBA) was aware of this in its 2009 decision to uphold the patent, to which Waugh replied “I wish they were”, which raised a few chuckles in the courtroom. Waugh added that he was not instructed to point this out to the TBA.



The judge highlighted the difficulties arising from the differences between the European and domestic patent systems. He said this was one of problems with hearing the same case in “different courts with different evidence”, and why there has been a push for a unitary patent system in Europe.



Lord Justice Chance added that there is, however, “the opportunity for more detail in the national courts than the TBA”, which does not allow for witnesses to be called or cross-examination.



There seems to be a divergence in opinion between the judges though, as Lord Justice Clarke remarked earlier, “it’s the same ball game, same players and the same materials”.



This morning, Thorley finished presenting HGS’s case from 10.30am until 12pm. He emphasised that “the facts are the same, though the legal judgment is different”, between the England & Wales courts and the EPO TBA.



He remarked that the rulings of Lord Justice Kitchin and Lord Justice Jacob were either “both right or they are both wrong”.



In closing HGS’s appeal, Thorley described the three levels of protein function, identified from the ZymoGenetics case (T0898/05) that can indicate potential industrial application.



“Any one of these three levels is acceptable” said Thorley. “No,” interrupted Lord Justice Neuberger, saying: “Might be acceptable” a point which Thorley conceded.



Waugh later argued that finding merely one of those three levels does not give industrial application. “It might and it might not, depending on the facts”, he said.



“Are you saying that you have to have found the application?” asked Hope.



“No, you have to set the reader on their way,” said Waugh.



When HGS filed its patent “it did not know the function on any of the three levels” he argued.



Thorley and the judges discussed what level of proof is necessary to describe potential therapeutic effects in a gene patent. Thorley said: “If you have to prove in vivo … patenting becomes the exclusive colony of the rich” and that “identifying a cellular function is enough”.



Previous rulings in the lower courts had borrowed the phrase “immediate concrete benefit” as the test for industrial applicability from the ZymoGenetics case.



Both Hope and Clarke agreed that the phrase was an odd use of the word “immediate” to which Neuberger added that it was the sort of case where there was a “weakness or slipperiness with words”.



Thorley argued that immediate does not mean that future research is unnecessary to envisage the industrial application.



“Anybody could read a patent and say, that is concrete, that is plausible and that is a hope for the future.” The TBA took this approach, whereas the England and Wales courts have not, he said.



Neuberger asked to what extent a patent should have predictions for uses. Waugh said that they need to be “derivable in a straightforward manner and should not require a research project to elicit the function”.



Hope said that “the fact the patent claims something which ultimately doesn’t work, doesn’t matter”.



Waugh explained that the patent teaches an activity on T & B cells, which are cells of the immune system, so an immune function is expected. However, the potential industrial application of the patent “does not confine itself to immune system disorders”.



It is not in the public interest to grant a monopoly on the wide claims for antibodies to Neutrokine-α relevant to many diseases, said Waugh, who was pressed extensively by the judges today.



The hearing continues at 10.30am and is expected to conclude tomorrow.



more from across site and SHARED ros bottom lb

More from across our site

In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Gift this article